Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma
Authors:
- T BánfalviTBT Bánfalvi
- T KremmerTKT Kremmer
- 1 January 2003
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (2) , 164-169
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Serum concentration of 5‐S‐cysteinyldopa in patients with melanomaEuropean Journal of Clinical Investigation, 2000
- The value of cysteinyldopa in the follow-up of disseminated malignant melanomaMelanoma Research, 2000
- Serum protein S100β in patients with malignant melanoma detected by an immunoluminometric assayJournal of Cancer Research and Clinical Oncology, 2000
- Clinical and prognostic relevance of serum S‐100β protein in malignant melanomaBritish Journal of Dermatology, 1998
- Elevated serum levels of S100 and survival in metastatic malignant melanomaBritish Journal of Cancer, 1997
- The Use of Serological Tumor Markers for Malignant MelanomaOncology Research and Treatment, 1997
- Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cellsMelanoma Research, 1996
- Clinical significance of serum S100 in metastatic malignant melanomaEuropean Journal of Cancer, 1995
- Evaluation of melanin-related metabolites as markers of melanoma progressionCancer, 1994